Indacaterol/glycopyrronium bromide
Combination drug / From Wikipedia, the free encyclopedia
Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:
- Indacaterol maleate—an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA);[2]
- Glycopyrronium bromide (glycopyrrolate)—a muscarinic anticholinergic.
Quick Facts Combination of, Glycopyrronium bromide ...
Combination of | |
---|---|
Indacaterol | Ultra-long-acting beta-adrenoceptor agonist |
Glycopyrronium bromide | Muscarinic anticholinergic |
Clinical data | |
Trade names | Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler |
Pregnancy category |
|
Routes of administration | Inhalation only |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG | |
CompTox Dashboard (EPA) |
Close
Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[3]
The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.[3][4] In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.[5]